By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS


Industry
Biotechnology






Company News
Janssen-Cilag International NV (JNJ) Release: EPREX (Epoetin Alfa) Marketing Authorization Extended To Include Treatment Of Symptomatic Anaemia In Patients With Low Or Intermediate-1-Risk Myelodysplastic Syndromes 3/24/2017 6:09:32 AM
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017 6:32:05 AM
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves STELARA (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease 11/11/2016 11:39:24 AM
Janssen-Cilag International NV (JNJ) Release:Treatment Outcome Data From The Prostate Cancer Registry Presented For The First Time At The 2016 European Society For Medical Oncology (ESMO) Congress 10/10/2016 11:45:44 AM
Janssen-Cilag International NV (JNJ) To Present Growing Set Of Oncology Data At The 2016 European Society For Medical Oncology (ESMO) Congress 9/29/2016 11:00:03 AM
Janssen-Cilag International NV (JNJ) To Present Growing Set Of Oncology Data At The 2016 European Society For Medical Oncology (ESMO) Congress 9/28/2016 11:52:21 AM
Janssen-Cilag International NV (JNJ) Receives CHMP Positive Opinion For STELARA (Ustekinumab) Recommending Approval For The Treatment Of Moderately To Severely Active Crohn’s Disease In The European Union 9/16/2016 8:12:39 AM
Janssen-Cilag International NV (JNJ) Submits Application To EMA To Expand Use Of DARZALEX (Daratumumab) To Include Combination With Standard Of Care Regimens 8/23/2016 9:40:30 AM
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016 11:01:13 AM
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016 10:46:41 AM
123456
//-->